Nicole Fabbri

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 18, 2025

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Journal: Blood advances

Published: August 20, 2025

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.

Journal: Blood advances

Published: August 20, 2025

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Grupo Español de Trasplante Hematopoyético y Terapia Celular.

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Grupo Español de Trasplante Hematopoyético y Terapia Celular.

Journal: Transplantation

Published: June 17, 2025

SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy.

SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy.

Journal: Annals of hematology

Published: March 31, 2025

Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice.

Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice.

Journal: Annals of hematology

Published: January 03, 2025

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study.

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study.

Journal: Blood advances

Published: December 09, 2024

Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma.

Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma.

Journal: European journal of haematology

Published: July 09, 2024

Energy exchange statistics and fluctuation theorem for nonthermal asymptotic states.

Energy exchange statistics and fluctuation theorem for nonthermal asymptotic states.

Journal: Physical review. E

Published: April 16, 2024

Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.

Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.

Journal: EClinicalMedicine

Published: January 27, 2024

CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers.

CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 09, 2023

Second-line treatment of diffuse large B-cell lymphoma: Evolution of options.

Second-line treatment of diffuse large B-cell lymphoma: Evolution of options.

Journal: Seminars in hematology

Published: November 02, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026